Cargando…

Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe

Male circumcision (MC) for sexually active, HIV-negative men reduces HIV transmission and averts HIV infections. Excluding HIV-positive men from MC decreases access to additional health and hygiene benefits. In settings where HIV-testing is, or is perceived to be, required for MC, testing may reduce...

Descripción completa

Detalles Bibliográficos
Autores principales: Tshimanga, Mufuta, Makunike-Chikwinya, Batsirai, Mangwiro, Tonderayi, Tapiwa Gundidza, Patricia, Chatikobo, Pesanai, Murenje, Vernon, Herman-Roloff, Amy, Kilmarx, Peter H., Holec, Marrianne, Gwinji, Gerald, Mugurungi, Owen, Murwira, Munyaradzi, Xaba, Sinokuthemba, Barnhart, Scott, Feldacker, Caryl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722373/
https://www.ncbi.nlm.nih.gov/pubmed/29220392
http://dx.doi.org/10.1371/journal.pone.0189146
_version_ 1783284998434979840
author Tshimanga, Mufuta
Makunike-Chikwinya, Batsirai
Mangwiro, Tonderayi
Tapiwa Gundidza, Patricia
Chatikobo, Pesanai
Murenje, Vernon
Herman-Roloff, Amy
Kilmarx, Peter H.
Holec, Marrianne
Gwinji, Gerald
Mugurungi, Owen
Murwira, Munyaradzi
Xaba, Sinokuthemba
Barnhart, Scott
Feldacker, Caryl
author_facet Tshimanga, Mufuta
Makunike-Chikwinya, Batsirai
Mangwiro, Tonderayi
Tapiwa Gundidza, Patricia
Chatikobo, Pesanai
Murenje, Vernon
Herman-Roloff, Amy
Kilmarx, Peter H.
Holec, Marrianne
Gwinji, Gerald
Mugurungi, Owen
Murwira, Munyaradzi
Xaba, Sinokuthemba
Barnhart, Scott
Feldacker, Caryl
author_sort Tshimanga, Mufuta
collection PubMed
description Male circumcision (MC) for sexually active, HIV-negative men reduces HIV transmission and averts HIV infections. Excluding HIV-positive men from MC decreases access to additional health and hygiene benefits. In settings where HIV-testing is, or is perceived to be, required for MC, testing may reduce MC uptake. Reducing promotion of HIV testing within MC settings and promoting device-based MC may speed MC scale-up. To assess safety and efficacy of PrePex MC device among HIV-positive men, we conducted a one-arm, open-label, prospective study in otherwise healthy HIV-positive men in Zimbabwe. METHODS: We aimed to determine if the adverse event (AE) rate was non-inferior to an AE rate of 2%, a rate considered the global standard of MC safety. Study procedures, AE definitions, and study staff were unchanged from previous PrePex Zimbabwe trials. After PrePex placement and removal, weekly visits assessed wound healing. Men returned on Day 90. Safety was defined as occurrence of moderate and serious clinical AEs. Efficacy was defined as ability to reach the endpoint of complete circumcision. RESULTS: Among 400 healthy, HIV-positive, consenting adults, median age was 40 years (IQR: 34, 46); 79.5% in WHO stage 2; median CD4 was 336.5c/μl (IQR: 232, 459); 337 (85%) on anti-retroviral therapy. Among 385 (96%) observed completely healed, median days to complete healing was 42 (IQR: 35–49). There was no association between time to healing and CD4 (p = 0.66). Four study-related severe AEs and no moderate AEs were reported: severe/moderate AE rate of 1.0% (95% CI: 0.27% to 2.5). This was non-inferior to 2% AEs (p = 0.0003). All AEs were device displacements resulting in surgical MC and, subsequently, complete healing. CONCLUSION: Male circumcision among healthy, HIV-positive men using PrePex is safe and effective. Reducing the barrier of HIV testing while improving counseling for safer sex practices among all MC clients could increase MC uptake and avert more HIV infections.
format Online
Article
Text
id pubmed-5722373
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-57223732017-12-15 Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe Tshimanga, Mufuta Makunike-Chikwinya, Batsirai Mangwiro, Tonderayi Tapiwa Gundidza, Patricia Chatikobo, Pesanai Murenje, Vernon Herman-Roloff, Amy Kilmarx, Peter H. Holec, Marrianne Gwinji, Gerald Mugurungi, Owen Murwira, Munyaradzi Xaba, Sinokuthemba Barnhart, Scott Feldacker, Caryl PLoS One Research Article Male circumcision (MC) for sexually active, HIV-negative men reduces HIV transmission and averts HIV infections. Excluding HIV-positive men from MC decreases access to additional health and hygiene benefits. In settings where HIV-testing is, or is perceived to be, required for MC, testing may reduce MC uptake. Reducing promotion of HIV testing within MC settings and promoting device-based MC may speed MC scale-up. To assess safety and efficacy of PrePex MC device among HIV-positive men, we conducted a one-arm, open-label, prospective study in otherwise healthy HIV-positive men in Zimbabwe. METHODS: We aimed to determine if the adverse event (AE) rate was non-inferior to an AE rate of 2%, a rate considered the global standard of MC safety. Study procedures, AE definitions, and study staff were unchanged from previous PrePex Zimbabwe trials. After PrePex placement and removal, weekly visits assessed wound healing. Men returned on Day 90. Safety was defined as occurrence of moderate and serious clinical AEs. Efficacy was defined as ability to reach the endpoint of complete circumcision. RESULTS: Among 400 healthy, HIV-positive, consenting adults, median age was 40 years (IQR: 34, 46); 79.5% in WHO stage 2; median CD4 was 336.5c/μl (IQR: 232, 459); 337 (85%) on anti-retroviral therapy. Among 385 (96%) observed completely healed, median days to complete healing was 42 (IQR: 35–49). There was no association between time to healing and CD4 (p = 0.66). Four study-related severe AEs and no moderate AEs were reported: severe/moderate AE rate of 1.0% (95% CI: 0.27% to 2.5). This was non-inferior to 2% AEs (p = 0.0003). All AEs were device displacements resulting in surgical MC and, subsequently, complete healing. CONCLUSION: Male circumcision among healthy, HIV-positive men using PrePex is safe and effective. Reducing the barrier of HIV testing while improving counseling for safer sex practices among all MC clients could increase MC uptake and avert more HIV infections. Public Library of Science 2017-12-08 /pmc/articles/PMC5722373/ /pubmed/29220392 http://dx.doi.org/10.1371/journal.pone.0189146 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Tshimanga, Mufuta
Makunike-Chikwinya, Batsirai
Mangwiro, Tonderayi
Tapiwa Gundidza, Patricia
Chatikobo, Pesanai
Murenje, Vernon
Herman-Roloff, Amy
Kilmarx, Peter H.
Holec, Marrianne
Gwinji, Gerald
Mugurungi, Owen
Murwira, Munyaradzi
Xaba, Sinokuthemba
Barnhart, Scott
Feldacker, Caryl
Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe
title Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe
title_full Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe
title_fullStr Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe
title_full_unstemmed Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe
title_short Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe
title_sort safety and efficacy of the prepex device in hiv-positive men: a single-arm study in zimbabwe
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722373/
https://www.ncbi.nlm.nih.gov/pubmed/29220392
http://dx.doi.org/10.1371/journal.pone.0189146
work_keys_str_mv AT tshimangamufuta safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe
AT makunikechikwinyabatsirai safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe
AT mangwirotonderayi safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe
AT tapiwagundidzapatricia safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe
AT chatikobopesanai safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe
AT murenjevernon safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe
AT hermanroloffamy safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe
AT kilmarxpeterh safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe
AT holecmarrianne safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe
AT gwinjigerald safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe
AT mugurungiowen safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe
AT murwiramunyaradzi safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe
AT xabasinokuthemba safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe
AT barnhartscott safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe
AT feldackercaryl safetyandefficacyoftheprepexdeviceinhivpositivemenasinglearmstudyinzimbabwe